The Skin Analysis and Epidermal Engineering Core was developed to enhance the productivity of all projects within this P01 by facilitating access and providing expertise in several important areas. The core will render state-of-the art embedding, sectioning (frozen or paraffin-embedded), routine staining, immunostaining, and creation of LRCs using retroviral constructs, in a timely and cost-efficient manner. Not only will conventional immunomarkers be available, but cutting-edge techniques with higher sensitivities and pathway specific immunoprobes aimed at defining: apoptosis markers, signal transduction pathways, and proliferation/differentiation pathways will also be used. All of the work performed in this core will be conducted by an experienced team with a track record of excellence and productivity. Cooperative interaction amongst members of this core and the projects will likely occur on a daily basis. Since Dr. Nickoloff has served as the Core Director for other relevant cores in the past such as the Immunopathology Core at the University of Michigan and the SCID Mouse Core at Loyola University, this expertise coupled with ongoing highly translational joint research efforts between Chicago and Ann Arbor will ensure the success of this core. The services will include the following: 1. To provide specialized handling of skin biopsy specimens derived from both human and murine tissues including cryopreservation and formalin fixation. 2. To provide routine staining (hematoxylin and eosin), as well as immunohistochemical staining of cryopreserved and paraffin embedded sections. 3. To provide expert dermatopathological reports of all stained sections with quantitative and semiquantitative measurements on all morphological analyses. 4. To prepare well-characterized retroviral constructs for transduction into epidermal equivalents (EEs) and Loyola raft cultures (LRCs) that will be utilized for in-vitro studies and skin graft experiments.
| Holtan, Shernan G; DeFor, Todd E; Panoskaltsis-Mortari, Angela et al. (2018) Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Adv 2:1882-1888 |
| Ortiz-Velez, Laura; Ortiz-Villalobos, Javiera; Schulman, Abby et al. (2018) Genome alterations associated with improved transformation efficiency in Lactobacillus reuteri. Microb Cell Fact 17:138 |
| Ferrara, James L M; Chaudhry, Mohammed S (2018) GVHD: biology matters. Hematology Am Soc Hematol Educ Program 2018:221-227 |
| Major-Monfried, Hannah; Renteria, Anne S; Pawarode, Attaphol et al. (2018) MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood 131:2846-2855 |
| Naymagon, Steven; Naymagon, Leonard; Wong, Serre-Yu et al. (2017) Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. Nat Rev Gastroenterol Hepatol 14:711-726 |
| Hartwell, Matthew J; Özbek, Umut; Holler, Ernst et al. (2017) An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight 2:e89798 |
| Stickel, N; Hanke, K; Marschner, D et al. (2017) MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia 31:2732-2741 |
| Ferrara, James Lm; Smith, Christopher M; Sheets, Julia et al. (2017) Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. J Clin Invest 127:2441-2451 |
| Miller, Holly K; Braun, Thomas M; Stillwell, Terri et al. (2017) Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 23:522-528 |
| Renteria, Anne S; Levine, John E; Ferrara, James L M (2016) Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease. Expert Opin Orphan Drugs 4:469-484 |
Showing the most recent 10 out of 231 publications
